ENTRY       hsa05230                    Pathway
NAME        Central carbon metabolism in cancer - Homo sapiens (human)
DESCRIPTION Malignant transformation of cells requires specific adaptations of cellular metabolism to support growth and survival. In the early twentieth century, Otto Warburg established that there are fundamental differences in the central metabolic pathways operating in malignant tissue. He showed that cancer cells consume a large amount of glucose, maintain high rate of glycolysis and convert a majority of glucose into lactic acid even under normal oxygen concentrations (Warburg's Effects). More recently, it has been recognized that the 'Warburg effect' encompasses a similarly increased utilization of glutamine. From the intermediate molecules provided by enhanced glycolysis and glutaminolysis, cancer cells synthesize most of the macromolecules required for the duplication of their biomass and genome. These cancer-specific alterations represent a major consequence of genetic mutations and the ensuing changes of signalling pathways in cancer cells. Three transcription factors, c-MYC, HIF-1 and p53, are key regulators and coordinate regulation of cancer metabolism in different ways, and many other oncogenes and tumor suppressor genes cluster along the signaling pathways that regulate c-MYC, HIF-1 and p53.
CLASS       Human Diseases; Cancer: overview
PATHWAY_MAP hsa05230  Central carbon metabolism in cancer
DRUG        D07257  Lonidamine (INN)
            D11090  Ivosidenib (JAN/USAN/INN)
            D11712  Pralsetinib (USAN/INN)
            D11713  Selpercatinib (JAN/USAN/INN)
            D11738  Telaglenastat (USAN/INN)
            D11739  Telaglenastat hydrochloride (USAN)
            D12354  Pralsetinib hydrate (JAN)
            D12443  Nanvuranlat hydrochloride hydrate (JAN)
            D12483  Olutasidenib (USAN/INN)
            D12600  Bezuclastinib (USAN/INN)
            D12708  Crelosidenib (USAN)
            D12717  Crelosidenib gentisate (USAN)
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        10000  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
            110117499  P3R3URF-PIK3R3; P3R3URF-PIK3R3 readthrough [KO:K02649]
            160287  LDHAL6A; lactate dehydrogenase A like 6A [KO:K00016] [EC:1.1.1.27]
            1956  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
            2064  ERBB2; erb-b2 receptor tyrosine kinase 2 [KO:K05083] [EC:2.7.10.1]
            207  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
            208  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
            2260  FGFR1; fibroblast growth factor receptor 1 [KO:K04362] [EC:2.7.10.1]
            2261  FGFR3; fibroblast growth factor receptor 3 [KO:K05094] [EC:2.7.10.1]
            2263  FGFR2; fibroblast growth factor receptor 2 [KO:K05093] [EC:2.7.10.1]
            2322  FLT3; fms related receptor tyrosine kinase 3 [KO:K05092] [EC:2.7.10.1]
            23410  SIRT3; sirtuin 3 [KO:K11413] [EC:2.3.1.286]
            2475  MTOR; mechanistic target of rapamycin kinase [KO:K07203] [EC:2.7.11.1]
            2539  G6PD; glucose-6-phosphate dehydrogenase [KO:K00036] [EC:1.1.1.49 1.1.1.363]
            2645  GCK; glucokinase [KO:K12407] [EC:2.7.1.2]
            27165  GLS2; glutaminase 2 [KO:K01425] [EC:3.5.1.2]
            2744  GLS; glutaminase [KO:K01425] [EC:3.5.1.2]
            3091  HIF1A; hypoxia inducible factor 1 subunit alpha [KO:K08268]
            3098  HK1; hexokinase 1 [KO:K00844] [EC:2.7.1.1]
            3099  HK2; hexokinase 2 [KO:K00844] [EC:2.7.1.1]
            3101  HK3; hexokinase 3 [KO:K00844] [EC:2.7.1.1]
            3265  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
            3417  IDH1; isocitrate dehydrogenase (NADP(+)) 1 [KO:K00031] [EC:1.1.1.42]
            3418  IDH2; isocitrate dehydrogenase (NADP(+)) 2 [KO:K00031] [EC:1.1.1.42]
            3815  KIT; KIT proto-oncogene, receptor tyrosine kinase [KO:K05091] [EC:2.7.10.1]
            3845  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
            3939  LDHA; lactate dehydrogenase A [KO:K00016] [EC:1.1.1.27]
            3945  LDHB; lactate dehydrogenase B [KO:K00016] [EC:1.1.1.27]
            3948  LDHC; lactate dehydrogenase C [KO:K00016] [EC:1.1.1.27]
            4233  MET; MET proto-oncogene, receptor tyrosine kinase [KO:K05099] [EC:2.7.10.1]
            441531  PGAM4; phosphoglycerate mutase family member 4 [KO:K01834] [EC:5.4.2.11]
            4609  MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377]
            4893  NRAS; NRAS proto-oncogene, GTPase [KO:K07828]
            4914  NTRK1; neurotrophic receptor tyrosine kinase 1 [KO:K03176] [EC:2.7.10.1]
            4916  NTRK3; neurotrophic receptor tyrosine kinase 3 [KO:K05101] [EC:2.7.10.1]
            51548  SIRT6; sirtuin 6 [KO:K11416] [EC:2.3.1.286]
            5156  PDGFRA; platelet derived growth factor receptor alpha [KO:K04363] [EC:2.7.10.1]
            5159  PDGFRB; platelet derived growth factor receptor beta [KO:K05089] [EC:2.7.10.1]
            5160  PDHA1; pyruvate dehydrogenase E1 subunit alpha 1 [KO:K00161] [EC:1.2.4.1]
            5161  PDHA2; pyruvate dehydrogenase E1 subunit alpha 2 [KO:K00161] [EC:1.2.4.1]
            5162  PDHB; pyruvate dehydrogenase E1 subunit beta [KO:K00162] [EC:1.2.4.1]
            5163  PDK1; pyruvate dehydrogenase kinase 1 [KO:K12077] [EC:2.7.11.2]
            5211  PFKL; phosphofructokinase, liver type [KO:K00850] [EC:2.7.1.11]
            5213  PFKM; phosphofructokinase, muscle [KO:K00850] [EC:2.7.1.11]
            5214  PFKP; phosphofructokinase, platelet [KO:K00850] [EC:2.7.1.11]
            5223  PGAM1; phosphoglycerate mutase 1 [KO:K01834] [EC:5.4.2.11]
            5224  PGAM2; phosphoglycerate mutase 2 [KO:K01834] [EC:5.4.2.11]
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            5295  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            5296  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            5315  PKM; pyruvate kinase M1/2 [KO:K00873] [EC:2.7.1.40]
            5594  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            5595  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            5604  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            5605  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            57103  TIGAR; TP53 induced glycolysis regulatory phosphatase [KO:K14634] [EC:3.1.3.46]
            5728  PTEN; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
            5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
            5979  RET; ret proto-oncogene [KO:K05126] [EC:2.7.10.1]
            6510  SLC1A5; solute carrier family 1 member 5 [KO:K05616]
            6513  SLC2A1; solute carrier family 2 member 1 [KO:K07299]
            6514  SLC2A2; solute carrier family 2 member 2 [KO:K07593]
            7157  TP53; tumor protein p53 [KO:K04451]
            80201  HKDC1; hexokinase domain containing 1 [KO:K00844] [EC:2.7.1.1]
            8140  SLC7A5; solute carrier family 7 member 5 [KO:K13780]
            8503  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            9123  SLC16A3; solute carrier family 16 member 3 [KO:K08180]
            92483  LDHAL6B; lactate dehydrogenase A like 6B [KO:K00016] [EC:1.1.1.27]
            9997  SCO2; synthesis of cytochrome C oxidase 2 [KO:K23755]
COMPOUND    C00022  Pyruvate
            C00024  Acetyl-CoA
            C00025  L-Glutamate
            C00026  2-Oxoglutarate
            C00031  D-Glucose
            C00036  Oxaloacetate
            C00037  Glycine
            C00041  L-Alanine
            C00042  Succinate
            C00049  L-Aspartate
            C00062  L-Arginine
            C00064  L-Glutamine
            C00065  L-Serine
            C00073  L-Methionine
            C00074  Phosphoenolpyruvate
            C00078  L-Tryptophan
            C00079  L-Phenylalanine
            C00082  L-Tyrosine
            C00085  D-Fructose 6-phosphate
            C00092  D-Glucose 6-phosphate
            C00097  L-Cysteine
            C00122  Fumarate
            C00123  L-Leucine
            C00135  L-Histidine
            C00148  L-Proline
            C00149  (S)-Malate
            C00152  L-Asparagine
            C00158  Citrate
            C00183  L-Valine
            C00186  (S)-Lactate
            C00197  3-Phospho-D-glycerate
            C00311  Isocitrate
            C00354  D-Fructose 1,6-bisphosphate
            C00407  L-Isoleucine
            C00631  2-Phospho-D-glycerate
            C00665  beta-D-Fructose 2,6-bisphosphate
            C00704  Superoxide
REFERENCE   PMID:23279446
  AUTHORS   Soga T
  TITLE     Cancer metabolism: key players in metabolic reprogramming.
  JOURNAL   Cancer Sci 104:275-81 (2013)
            DOI:10.1111/cas.12085
REFERENCE   PMID:19460998
  AUTHORS   Vander Heiden MG, Cantley LC, Thompson CB
  TITLE     Understanding the Warburg effect: the metabolic requirements of cell proliferation.
  JOURNAL   Science 324:1029-33 (2009)
            DOI:10.1126/science.1160809
REFERENCE   PMID:23071355
  AUTHORS   Teicher BA, Linehan WM, Helman LJ
  TITLE     Targeting cancer metabolism.
  JOURNAL   Clin Cancer Res 18:5537-45 (2012)
            DOI:10.1158/1078-0432.CCR-12-2587
REFERENCE   PMID:21127244
  AUTHORS   Levine AJ, Puzio-Kuter AM
  TITLE     The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes.
  JOURNAL   Science 330:1340-4 (2010)
            DOI:10.1126/science.1193494
REFERENCE   PMID:24079832
  AUTHORS   Amoedo ND, Valencia JP, Rodrigues MF, Galina A, Rumjanek FD
  TITLE     How does the metabolism of tumour cells differ from that of normal cells.
  JOURNAL   Biosci Rep 33:e00080 (2013)
            DOI:10.1042/BSR20130066
REFERENCE   PMID:21258394
  AUTHORS   Cairns RA, Harris IS, Mak TW
  TITLE     Regulation of cancer cell metabolism.
  JOURNAL   Nat Rev Cancer 11:85-95 (2011)
            DOI:10.1038/nrc2981
REFERENCE   PMID:22237205
  AUTHORS   Munoz-Pinedo C, El Mjiyad N, Ricci JE
  TITLE     Cancer metabolism: current perspectives and future directions.
  JOURNAL   Cell Death Dis 3:e248 (2012)
            DOI:10.1038/cddis.2011.123
REFERENCE   PMID:22156302
  AUTHORS   Cairns RA, Harris I, McCracken S, Mak TW
  TITLE     Cancer cell metabolism.
  JOURNAL   Cold Spring Harb Symp Quant Biol 76:299-311 (2011)
            DOI:10.1101/sqb.2011.76.012856
REFERENCE   PMID:18538731
  AUTHORS   Kroemer G, Pouyssegur J
  TITLE     Tumor cell metabolism: cancer's Achilles' heel.
  JOURNAL   Cancer Cell 13:472-82 (2008)
            DOI:10.1016/j.ccr.2008.05.005
REFERENCE   PMID:18177721
  AUTHORS   DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB
  TITLE     The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.
  JOURNAL   Cell Metab 7:11-20 (2008)
            DOI:10.1016/j.cmet.2007.10.002
REFERENCE   PMID:21508971
  AUTHORS   Koppenol WH, Bounds PL, Dang CV
  TITLE     Otto Warburg's contributions to current concepts of cancer metabolism.
  JOURNAL   Nat Rev Cancer 11:325-37 (2011)
            DOI:10.1038/nrc3038
REFERENCE   PMID:21801601
  AUTHORS   Fogg VC, Lanning NJ, Mackeigan JP
  TITLE     Mitochondria in cancer: at the crossroads of life and death.
  JOURNAL   Chin J Cancer 30:526-39 (2011)
            DOI:10.5732/cjc.011.10018
REFERENCE   PMID:16982728
  AUTHORS   Kim JW, Dang CV
  TITLE     Cancer's molecular sweet tooth and the Warburg effect.
  JOURNAL   Cancer Res 66:8927-30 (2006)
            DOI:10.1158/0008-5472.CAN-06-1501
REFERENCE   PMID:18766298
  AUTHORS   Yeung SJ, Pan J, Lee MH
  TITLE     Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer.
  JOURNAL   Cell Mol Life Sci 65:3981-99 (2008)
            DOI:10.1007/s00018-008-8224-x
REFERENCE   PMID:23897900
  AUTHORS   Li B, Simon MC
  TITLE     Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.
  JOURNAL   Clin Cancer Res 19:5835-41 (2013)
            DOI:10.1158/1078-0432.CCR-12-3629
REFERENCE   PMID:22307140
  AUTHORS   Shen L, Sun X, Fu Z, Yang G, Li J, Yao L
  TITLE     The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy.
  JOURNAL   Clin Cancer Res 18:1561-7 (2012)
            DOI:10.1158/1078-0432.CCR-11-3040
REFERENCE   PMID:19270154
  AUTHORS   Jones RG, Thompson CB
  TITLE     Tumor suppressors and cell metabolism: a recipe for cancer growth.
  JOURNAL   Genes Dev 23:537-48 (2009)
            DOI:10.1101/gad.1756509
REFERENCE   PMID:21340684
  AUTHORS   Maddocks OD, Vousden KH
  TITLE     Metabolic regulation by p53.
  JOURNAL   J Mol Med (Berl) 89:237-45 (2011)
            DOI:10.1007/s00109-011-0735-5
REFERENCE   PMID:22750268
  AUTHORS   Chen JQ, Russo J
  TITLE     Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells.
  JOURNAL   Biochim Biophys Acta 1826:370-84 (2012)
            DOI:10.1016/j.bbcan.2012.06.004
REFERENCE   PMID:20520704
  AUTHORS   Kaelin WG Jr, Thompson CB
  TITLE     Q&amp;A: Cancer: clues from cell metabolism.
  JOURNAL   Nature 465:562-4 (2010)
            DOI:10.1038/465562a
REFERENCE   PMID:24113830
  AUTHORS   Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G
  TITLE     Metabolic targets for cancer therapy.
  JOURNAL   Nat Rev Drug Discov 12:829-46 (2013)
            DOI:10.1038/nrd4145
REFERENCE   PMID:24738035
  AUTHORS   Phan LM, Yeung SC, Lee MH
  TITLE     Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies.
  JOURNAL   Cancer Biol Med 11:1-19 (2014)
            DOI:10.7497/j.issn.2095-3941.2014.01.001
REFERENCE   PMID:22101401
  AUTHORS   Icard P, Poulain L, Lincet H
  TITLE     Understanding the central role of citrate in the metabolism of cancer cells.
  JOURNAL   Biochim Biophys Acta 1825:111-6 (2012)
            DOI:10.1016/j.bbcan.2011.10.007
REFERENCE   PMID:22349059
  AUTHORS   Daye D, Wellen KE
  TITLE     Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis.
  JOURNAL   Semin Cell Dev Biol 23:362-9 (2012)
            DOI:10.1016/j.semcdb.2012.02.002
REFERENCE   PMID:23018234
  AUTHORS   Chiarugi A, Dolle C, Felici R, Ziegler M
  TITLE     The NAD metabolome--a key determinant of cancer cell biology.
  JOURNAL   Nat Rev Cancer 12:741-52 (2012)
            DOI:10.1038/nrc3340
REFERENCE   PMID:24398961
  AUTHORS   Guarente L
  TITLE     The many faces of sirtuins: Sirtuins and the Warburg effect.
  JOURNAL   Nat Med 20:24-5 (2014)
            DOI:10.1038/nm.3438
REFERENCE   PMID:15916903
  AUTHORS   Fuchs BC, Bode BP
  TITLE     Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?
  JOURNAL   Semin Cancer Biol 15:254-66 (2005)
            DOI:10.1016/j.semcancer.2005.04.005
REL_PATHWAY hsa00010  Glycolysis / Gluconeogenesis
            hsa00020  Citrate cycle (TCA cycle)
            hsa00030  Pentose phosphate pathway
            hsa00190  Oxidative phosphorylation
            hsa00250  Alanine, aspartate and glutamate metabolism
            hsa00260  Glycine, serine and threonine metabolism
            hsa00330  Arginine and proline metabolism
            hsa01212  Fatty acid metabolism
            hsa04010  MAPK signaling pathway
            hsa04066  HIF-1 signaling pathway
            hsa04150  mTOR signaling pathway
            hsa04151  PI3K-Akt signaling pathway
KO_PATHWAY  ko05230
///
